GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Accounts Payable

ZBIO (Zenas BioPharma) Accounts Payable : $17.14 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Accounts Payable?

Zenas BioPharma's Accounts Payable for the quarter that ended in Dec. 2024 was $17.14 Mil.

Zenas BioPharma's quarterly Accounts Payable increased from Jun. 2024 ($8.36 Mil) to Sep. 2024 ($15.08 Mil) and increased from Sep. 2024 ($15.08 Mil) to Dec. 2024 ($17.14 Mil).

Zenas BioPharma's annual Accounts Payable declined from Dec. 2022 ($5.82 Mil) to Dec. 2023 ($5.40 Mil) but then increased from Dec. 2023 ($5.40 Mil) to Dec. 2024 ($17.14 Mil).


Zenas BioPharma Accounts Payable Historical Data

The historical data trend for Zenas BioPharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Accounts Payable Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24
Accounts Payable
5.82 5.40 17.14

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Payable Get a 7-Day Free Trial Premium Member Only 5.40 8.83 8.36 15.08 17.14

Zenas BioPharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Zenas BioPharma Accounts Payable Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenas BioPharma Business Description

Traded in Other Exchanges
N/A
Address
852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.